Advertisement

Topics

SYNERGY: Anti-LINGO Agent Misses Primary Endpoint in MS

04:25 EDT 23 Sep 2016 | Medscape

Opicinumab, a novel remyelinating agent, didn't show a 'linear dose response' of clinical improvement across 4 treatment groups. But it may still have potential for certain patients, say experts.
Medscape Medical News

Original Article: SYNERGY: Anti-LINGO Agent Misses Primary Endpoint in MS

NEXT ARTICLE

More From BioPortfolio on "SYNERGY: Anti-LINGO Agent Misses Primary Endpoint in MS"

Quick Search
Advertisement